Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.

摘要: BACKGROUND Blood protein markers that provide more accurate or earlier diagnosis of prostate cancer should have a positive impact on treatment and management. METHODS Serum samples from control subjects patients with benign malignant prostatic disease were analyzed antibody arrays targeting multiple candidate detected two-color, rolling-circle amplification (TC-RCA). The measurements certain antibodies validated using immunoblots, immunoprecipitation/mass spectrometry, sandwich immunoassays. RESULTS Several potential disease-associated alterations uncovered. most significant was thrombospondin-1, which strongly elevated in repressed cancer. Thrombospondin-1 levels did not correlate prostate-specific antigen (PSA) differentiated 79% sensitivity 81% specificity. CONCLUSIONS The measurement thrombospondin-1 could be used to assist the decision obtain biopsy men suspected cancer, lead reduction number unnecessary biopsies. Prostate 67:255–267, 2007. © 2006 Wiley-Liss, Inc.